Cohance Lifesciences

1,006.60
-3.00
(-0.30%)
Market Cap
38,509.21 Cr
EPS
11.80
PE Ratio
143.81
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,119.00
52 Week Low
974.90
PB Ratio
22.53
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,644.20
#1 3,94,498.66
34.46
#1 49,887.20
12.06
#1 9,648
-18.99
36.89
6,538.00
1,73,563.36
79.22
8,184.00
0.89
1,600
23.05
52.65
1,491.90
1,20,488.07
22.95
26,520.70
14.17
4,155
30.28
50.44
1,321.60
1,10,281.62
19.37
28,905.40
12.36
5,578
21.14
61.31
3,187.40
1,07,876.10
56.64
10,785.70
11.59
1,656
10.91
51.94
954.30
96,024.91
20.64
19,831.50
13.82
3,831
-0.19
60.33
2,313.70
95,458.29
48.91
10,615.60
19.57
1,942
-10.91
40.24
1,932.90
88,244.80
27.19
20,141.50
#1 19.94
1,936
#1 112.49
43.06
31,750.00
67,466.53
47.34
6,097.20
10.80
1,201
27.83
58.17
1,092.50
63,452.58
#1 18.61
29,559.20
17.55
3,169
-0.50
35.01
Forecast
Actual
Growth Rate
Revenue Growth
-19.72 %
Net Income Growth
-26.99 %
Cash Flow Change
-21.59 %
ROE
-38.23 %
ROCE
-39.27 %
EBITDA Margin (Avg.)
-6.12 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
251
217
282
190
211
254
247
296
281
293
324
456
381
350
289
367
381
358
251
234
270
249
272
323
413
Expenses
129
95
147
99
108
126
140
138
166
149
179
206
207
188
179
207
198
181
133
154
180
151
154
189
329
EBITDA
122
122
135
91
103
128
107
158
116
144
144
251
174
162
111
160
183
178
118
80
90
98
118
133
84
Operating Profit %
49 %
52 %
46 %
45 %
41 %
47 %
41 %
50 %
36 %
43 %
40 %
48 %
43 %
45 %
36 %
41 %
47 %
48 %
42 %
30 %
29 %
35 %
40 %
38 %
18 %
Depreciation
6
6
6
6
7
7
8
9
8
9
9
11
10
12
12
12
12
13
12
13
17
13
17
20
27
Interest
2
4
4
8
7
3
3
2
2
2
1
1
2
2
0
1
5
1
1
2
2
2
2
3
6
Profit Before Tax
115
113
125
78
89
118
97
148
106
133
134
240
161
149
99
146
166
164
105
66
71
83
100
110
52
Tax
40
21
32
20
15
26
23
34
22
28
37
79
70
41
26
38
42
43
26
19
18
22
18
26
13
Net Profit
75
92
93
58
74
92
74
114
83
105
97
160
92
108
72
108
124
121
80
47
53
61
82
83
39
EPS in ₹
5.88
7.22
3.65
4.55
5.83
3.60
2.91
4.46
3.27
4.13
3.81
6.29
3.60
4.22
2.83
4.23
4.87
4.74
3.13
1.84
2.10
2.39
3.23
3.26
1.65

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
783
1,173
1,475
1,830
1,966
2,254
Fixed Assets
271
357
441
534
663
670
Current Assets
390
392
565
1,128
1,011
1,263
Capital Work in Progress
111
102
96
30
165
179
Investments
7
338
542
598
536
905
Other Assets
394
376
395
667
601
501
Total Liabilities
783
1,173
1,475
1,830
1,966
2,254
Current Liabilities
158
200
220
210
159
107
Non Current Liabilities
35
128
74
92
72
97
Total Equity
590
845
1,181
1,527
1,735
2,051
Reserve & Surplus
578
832
1,155
1,502
1,710
2,025
Share Capital
13
13
26
26
26
26

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
11
1
-5
37
20
-18
Investing Activities
-66
-414
-311
-136
-195
-362
Operating Activities
50
407
383
330
457
359
Financing Activities
26
7
-76
-157
-242
-14

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
May 2025
Promoter
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
50.10 %
50.10 %
50.10 %
50.10 %
50.10 %
66.41 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.01 %
10.14 %
9.54 %
9.80 %
10.70 %
10.84 %
11.05 %
7.38 %
DIIs
4.30 %
4.47 %
4.94 %
5.24 %
5.91 %
6.32 %
10.52 %
11.35 %
11.43 %
9.23 %
14.14 %
15.94 %
17.24 %
17.42 %
16.94 %
16.68 %
16.60 %
11.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
20.87 %
19.86 %
19.21 %
18.38 %
17.07 %
16.86 %
14.69 %
14.01 %
12.76 %
12.80 %
11.76 %
10.87 %
10.51 %
10.08 %
9.75 %
9.81 %
9.68 %
6.63 %
Others
14.84 %
15.68 %
15.86 %
16.38 %
17.02 %
16.82 %
14.78 %
14.64 %
15.81 %
17.97 %
4.08 %
3.04 %
12.59 %
12.59 %
12.50 %
12.56 %
12.55 %
8.55 %
No of Share Holders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 5 2 5 6 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 1.01 0.32 1.06 0.89 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 May 2025 1,151.25 1,092.65
07 May 2025 CHANGE OF NAME Change Of Name
NA
07 May 2025 1,118.50 1,118.50
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 1,148.20 1,084.55
28 Nov 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
28 Nov 2024 1,266.90 1,259.05
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 1,197.40 1,250.60
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 848.75 990.80
15 Dec 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
15 Dec 2023 572.10 673.25
12 Sept 2022 DIVIDEND Dividend
₹ 5.00 /share
09 Sept 2022 492.90 477.85
12 Sept 2022 DIVIDEND Dividend
₹ 1.00 /share
09 Sept 2022 492.90 477.85
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 580.15 507.45
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 580.15 507.45
16 Feb 2022 DIVIDEND Dividend
₹ 2.00 /share
15 Feb 2022 558.50 522.45
16 Feb 2022 DIVIDEND Dividend
₹ 1.00 /share
15 Feb 2022 558.50 522.45
17 Aug 2021 DIVIDEND Dividend
₹ 1.00 /share
13 Aug 2021 514.80 559.70
18 Feb 2021 DIVIDEND Dividend
₹ 1.00 /share
17 Feb 2021 486.60 494.65
28 Sept 2020 BONUS Bonus
1:1
25 Sept 2020 383.55 383.70

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
Financial Results For Period Ended March 31 2025May 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 28, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
General AnnouncementMay 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Change In The Name And Trading SymbolMay 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 13, 2025
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.May 12, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.May 12, 2025
Announcement under Regulation 30 (LODR)-AllotmentMay 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
Announcement under Regulation 30 (LODR)-Change of Company NameMay 07, 2025
Intimation Of Effective Date Of Merger And Record DateApr 25, 2025
Update On MergerApr 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Cautionary Email Received From The Stock ExchangeApr 02, 2025
Cautionary Email Received From The Stock ExchangeApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 28, 2025
Update On MergerMar 27, 2025
Closure of Trading WindowMar 26, 2025
Board Meeting Intimation for To Consider And Approve The Financial Results For The Period Ended March 31 2025Mar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 15, 2025

Technical Indicators

RSI(14)
Neutral
40.65
ATR(14)
Less Volatile
38.32
STOCH(9,6)
Neutral
21.97
STOCH RSI(14)
Neutral
24.88
MACD(12,26)
Bearish
-2.13
ADX(14)
Strong Trend
26.46
UO(9)
Bearish
46.04
ROC(12)
Downtrend And Accelerating
-1.26
WillR(14)
Neutral
-66.98

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Manufacturing Fund Direct - Growth
0.49%
560510
0.49%
0.49%
HSBC Small Cap Fund Direct-Growth
1.14%
-550218
-0.63%
-0.68%
Axis Small Cap Fund Direct-Growth
0.72%
400000
0.07%
0.05%
HDFC Pharma And Healthcare Fund Direct - Growth
1.95%
100000
0.46%
0.41%
Tata Flexi Cap Fund Direct - Growth
0.00%
-99280
-0.36%
-1.78%
Mirae Asset Healthcare Fund Direct - Growth
3.88%
96480
0.07%
-0.07%
360 ONE Focused Equity Fund Direct-Growth
2.11%
92518
-0.17%
-0.13%
Samco Active Momentum Fund Direct - Growth
1.28%
74868
0.88%
0.89%
Mirae Asset Small Cap Fund Direct-Growth
1.70%
27810
-0.18%
-0.02%
Union Aggressive Hybrid Fund Direct - Growth
0.42%
26324
0.42%
0.42%
360 ONE FlexiCap Fund Direct - Growth
2.18%
15373
-0.42%
-0.48%
Motilal Oswal Active Momentum Fund Direct - Growth
0.00%
-15208
-3.26%
-3.29%
UTI Flexi Cap Fund Direct-Growth
0.75%
-13361
-0.08%
-0.11%
HDFC MNC Fund Direct - Growth
0.99%
10000
0.09%
0.99%
Union Midcap Fund Direct - Growth
0.73%
9106
-0.04%
0.73%
ITI Value Fund Direct - Growth
1.84%
7269
-0.03%
-0.07%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
1.33%
6235
-0.20%
-0.28%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.70%
3917
-0.13%
-0.16%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
1.33%
3416
-0.20%
-0.28%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.70%
2377
-0.13%
-0.16%
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth
1.77%
2268
-0.30%
-0.37%
ITI Pharma and Healthcare Fund Direct - Growth
4.84%
1993
-0.36%
-0.55%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.70%
1637
-0.13%
-0.16%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.70%
1006
-0.13%
-0.16%
JM Aggressive Hybrid Fund Direct-Growth
1.56%
-1000
-0.19%
0.16%

About Cohance Lifesciences

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Chairperson NameVIVEK SHARMA